Muscle-invasive bladder cancer treatment
When bladder cancer has invaded the muscle layer, the most common treatment is surgery to remove the whole bladder. Other treatments, such as chemotherapy and radiation therapy, may be given before or after surgery. A small number of muscle-invasive bladder cancers may be treated with a simpler surgery (TURBT), followed by chemotherapy combined with radiation therapy. This is known as trimodal therapy.
Learn more about:
- Making treatment decisions
- Surgery: cystectomy
- Systemic chemotherapy
- Radiation therapy
- Trimodal therapy
Urothelial carcinoma of the ureter or kidney
While urothelial carcinoma is the most common form of bladder cancer, it occasionally occurs in a ureter or part of the kidney (renal pelvis).
Much of this information about bladder cancer will be relevant if you have been diagnosed with urothelial cancer of the ureter or kidney. Symptoms include blood in the urine and back pain. Many of the same tests will be used for diagnosis, but instead of a cystoscopy, you will have a ureteroscopy.
This uses a ureteroscope, a thin instrument with a light, to examine the ureters and kidneys.
The most common treatment is surgery to remove the affected kidney, ureter and part of the bladder (nephroureterectomy). Sometimes, only part of the kidney or ureter needs to be removed, and in some cases a laser can be sent through a ureteroscope to remove the tumour. You may have chemotherapy or immunotherapy after the surgery.
Download a PDF booklet on this topic.
Prof Dickon Hayne, UWA Medical School, The University of Western Australia, and Head, Urology, South Metropolitan Health Service, WA; BEAT Bladder Cancer Australia; Dr Anne Capp, Senior Staff Specialist, Radiation Oncology, Calvary Mater Newcastle, NSW; Marc Diocera, Genitourinary Nurse Consultant, Peter MacCallum Cancer Centre, VIC; Dr Peter Heathcote, Senior Urologist, Princess Alexandra Hospital, and Adjunct Professor, Australian Prostate Cancer Research Centre, QLD; Melissa Le Mesurier, Consumer; Dr James Lynam, Medical Oncologist Staff Specialist, Calvary Mater Newcastle and The University of Newcastle, NSW; John McDonald, Consumer; Michael Twycross, Consumer; Rosemary Watson, 13 11 20 Consultant, Cancer Council Victoria.
View the Cancer Council NSW editorial policy.